HLS:CC News and Press, HLS Therapeutics Inc. From 06/22/22

HLS Therapeutics Obtains Public Reimbursement for Vascepa® in New Brunswick and with other Public Payors Canada NewsWire New Brunswick , Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will...

HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO , June 17, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces vot...

HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 22, 2022 Canada NewsWire TORONTO , June 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiov...

HLS Therapeutics to Present at the 2022 Jefferies Healthcare Conference Canada NewsWire TORONTO , June 1, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular...

HLS Therapeutics Executive Chairman and Co-Founder Bill Wells to Retire Canada NewsWire Co-Founder and Director Greg Gubitz appointed Chair of the Board of HLS TORONTO , May 24, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (...

HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec Canada NewsWire Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease Private drug plan...

HLS Therapeutics Announces Q1 Fiscal 2022 Financial Results Canada NewsWire Q1 2022 revenue of $14.6 million , Adjusted EBITDA of $6.3 million and cash from operations of $5.8 million . Vascepa® prescriptions grew 12% sequentially and 111% ye...

HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , April 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2022 financial results on ...

HLS Therapeutics completes negotiations with pCPA for Vascepa® Canada NewsWire Enters into Letter of Intent (LOI) that paves the way for product listing agreements for Vascepa with all of Canada's provinces and territories. Public market access is ex...

HLS Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO , April 25, 2022 /CNW/ - HLS Therapeuti...